• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Synergy Spine Solutions

Synergy Spine Solutions

Restoring Balance to Motion Preservation

  • Synergy Disc
    • Approval & IDE Study
  • Company
    • About Synergy Spine Solutions
    • Approval & IDE Study
    • Patents
    • Publications
  • Careers 
  • News & Events
  • Distributors
  • Contact

Press Releases

Synergy Spine Solutions® Receives FDA Approval for its Synergy Disc®, Expanding Cervical Disc Replacement Options for U.S. Patients

February 27, 2026 by Jessica Wicks

Milestone approval advances a new category of artificial cervical disc technology uniquely engineered to preserve motion and improve spinal alignment Louisville, CO – Feb. 27, 2026 – Synergy Spine Solutions®, a medical device company focused on improving the quality of life for patients undergoing spine surgery, today announced it has received U.S. Food and Drug Administration (FDA) […]

Filed Under: Press Releases

Synergy Spine Solutions and Johnson & Johnson MedTech Extend Strategic Collaboration into Germany

October 7, 2025 by OrthoCG

Louisville, Colorado – October 1 – Synergy Spine Solutions, an innovative orthopaedic medical device company focused on artificial cervical disc replacement, today announced the expansion of its sales agency agreement with Johnson & Johnson MedTech Germany. This agreement builds on the success of the existing sales agency agreements with Johnson & Johnson Medtech across the […]

Filed Under: Press Releases

Synergy Spine Solutions Appoints Troy Wahlenmaier as Chief Commercial Officer

August 14, 2025 by OrthoCG

Synergy Spine Solutions

August 14, 2025 – Louisville, CO – Synergy Spine Solutions Inc., a leading innovator in artificial cervical disc replacement, today announced the appointment of Troy Wahlenmaier as Chief Commercial Officer (CCO). In this role, Mr. Wahlenmaier will lead global sales and marketing efforts as the company accelerates its growth and prepares for U.S. commercialization. With more […]

Filed Under: Press Releases

Synergy Spine Solutions and Johnson & Johnson MedTech Extend Strategic Collaboration into Switzerland

July 14, 2025 by OrthoCG

Synergy 1-Level IDE Study

Louisville, Colorado – July 14 2025 – Synergy Spine Solutions, an innovative orthopaedic medical device company focused on artificial cervical disc replacement, today announced the expansion of its sales agency agreement with Johnson & Johnson MedTech Switzerland. The expansion of this agreement into Switzerland is effective April 1, 2025, and builds on the success of […]

Filed Under: Press Releases

2024 in review: a year of milestones and momentum at Synergy Spine Solutions

January 13, 2025 by OrthoCG

The past year has been one of transformative growth and accomplishment at Synergy Spine Solutions. From securing pivotal funding to achieving significant clinical trial milestones and expanding our global footprint, we are proud to share the highlights of 2024. Keep reading to discover how we reaffirmed our commitment to elevating the standard of care in […]

Filed Under: Press Releases

Synergy Spine Solutions announces completion of patient enrollment in the Synergy Disc® 2-Level IDE clinical trial

September 25, 2024 by OrthoCG

LOUISVILLE, Colo., Sept. 25, 2024 /PRNewswire/ — Synergy Spine Solutions Ltd, an innovative orthopedic medical device developer focused on artificial cervical disc replacement, today announced that it has completed patient enrollment in its U.S. 2-Level IDE clinical trial. Conducted under a U.S. Investigational Device Exemption (IDE), the 2-Level trial will evaluate the safety and effectiveness of the Synergy […]

Filed Under: Press Releases

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Footer

Phone: +1.647.692.3493
Email: info@synergyspinesolutions.com

United States Office
357 S. McCaslin Blvd, Suite 120
Louisville, CO 80027, USA

  • Home
  • Synergy Disc
  • Company
  • Careers 
  • News & Events
  • Distributors
  • Contact

Copyright © 2026 Synergy Spine Solutions Inc. All Right Reserved. · Privacy Policy
230-00001 REVM